Nitrous oxide (N 2 0) is an anesthetic gas known to produce an analgesic effect at subanesthetic concentrations. This analgesic property of N 2 0 can be clinically exploited in a broad range of conditions where pain relief is indicated. The mechanism of this analgesic effect was long thought to be nonspecific in nature, but a landmark study by Berkowitz and others in 1976 first implicated an opioid mechanism of action, possibly via N 2 0-stimulated neuronal release of endogenous opioid peptides to activate opioid receptors. N 2 0-induced release of opioid peptide has been demonstrated in both in vivo and in vitro preparations. Reversal of N 2 0 -i nduced antinociception in animals by narcotic antagonists has been reported by a number of laboratories. Subsequent studies have utilized more selective opioid antagonists to identify the opioid receptor subtypes involved in the antinociceptive effect of N 2 0. Extensive pharmacological testing in the mouse abdominal constriction and rat hot plate paradigms have establi shed that N 2 0-induced antinociception is mediated by K-opioid receptors in the former and byµ,-and f-opioid receptors in the latter. Current studies focus on two recent developments. The poor responsiveness of the DBA/2J mouse strain to N 2 0 has led to pharmacogenetic studies that hope to identify the underlying genetic basis for antinociceptive responsiveness to N 2 0 . Other research suggests an involvement of nitric oxide (NO) in mediating the antinociceptive effects of N 2 0 in both rats and mice.
Introduction
N 2 O is one of the simpler inorganic chemicals that is utilized clinically. First identified by Joseph Priestley some 200 years ago, N 2 0 possesses three outstanding clinical properties. First, it produces analgesia. The analgesic effect caused by inhalation of 20% N 2 O in oxygen is reportedly equivalent to that evoked by 15 mg morphine sulfate (9) . N 2 O-induced analgesia has been utilized to relieve pain associated with childbirth (40) , myocardial infarction (36, 73) , diagnostic or interventional procedures (6, 29, 35) , postsurgical recovery (23, 50, 51) , intractable pain (38) , refractory pain (16) , and accident and trauma (2, 12, 72) . Second, N 2 O produces an anesthetic effect. N 2 O enjoys a prominent role in medical history because it was the first drug used for surgical anesthesia. Despite its low anesthetic potency, it continues to be widely used in anesthesiology because of its ability to reduce the minimum alveolar concentration of other inhalation agents. Third, N 2 O produces a significant anxiolytic effect. In clinical dentistry, it is popularly used for
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producing conscious sedation, a state in which patients experience reduced anxiety and pain (67) . Recent research indicates that this antianxiety effect is distinct from the analgesic action of NP and may be mediated by central benzodiazepine mechanisms (13 ,57,64) .
The Opioid Nature of N 2 0-Induced Antinociception
The ability of inhaled N 2 O to suppress pain was first reported in 1800 by Sir Humphry Davy, who suggested that it might be used to relieve pain during surgical operations (68) . Surgical anesthesia was first demonstrated by Horace Wells in 1844, who had one of his own teeth extracted painlessly while he was under N 2 O. Though N 2 O was used for dental extractions and other surgical procedures for many years, its mechanism of action was ascribed to be a nebulous "nonspecific" action on the brain, most probably the result of a generalized depression of central nervous system function (69) .
Most studies of N 2 O-induced antinociception in mice have been carried out using the abdominal constriction test. In this procedure, mice receive an intraperitoneal (i.p.) injection of a dilute concentration of a chemical irritant such as phenylquinone or glacial acetic acid. Exactly 5 min later, the number of abdominal constrictions (i.e., lengthwise stretches of the torso with concave arching of the back) are counted for a fixed period. Exposure to increasing concentrations of N 2 O causes a doserelated suppression in the number of abdominal constrictions induced by i.p. injection of phenylquinone or dilute acetic acid (5 ,58) . The first evidence suggesting a specific mechanism of action was provided by Berkowitz and coworkers, who reported that the antinociceptive effect ofN 2 O in mice was significantly reduced by subcutaneous (s.c.) pretreatment with 5.0 mg/kg naloxone or naltrexone (4, 5) . Quock and associates have conducted more extensive dose-response studies, in which increasing s.c. pretreatment doses (1.0-10 mg/kg) of naloxone caused a progressive shift to the right of the doseresponse curve for N 2 O-induced antinociception (56) .
Pretreatment with 10 mg/kg ( + )-naloxone, s.c., was completely ineffective in influencing N 2 O-induced antinociception, demonstrating that the ability of naloxone to attenuate N 2 O was a stereospecific drug effect at the opioid receptor and not the consequence of some nonspecific action of naloxone (58) .
Systemic pretreatment with 10 mg/kg naltrexone methylbromide was also ineffective in altering N 2 0-induced antinociception (58) . However, following intracerebroventricular (i.e. v .) pretreatment with this quaternary ammonium form of naltrexone, there was an attenuation in N 2 O-induced antinociception. Because naltrexone methyl bromide does not penetrate the bloodbrain barrier, these findings implicate opioid receptors in the central nervous system as being responsible for mediating N 2 O-induced antinociception. Spinal cord opioid receptors are also involved in N 2 O-induced antinociception because intrathecal (i.t.) pretreatment with 0.5-5.0 µg naloxone causes a dose-dependent reduction in N 2 O-induced antinociception (55) .
Although most N 2 O studies in mice have been conducted in the abdominal constriction test, some investigations have utilized the hot plate paradigm. In this test, N 2 O-induced antinociception was antagonized by pretreatment with 20 mg/kg naloxone s.c. (66) but not by doses of ( + )-naloxone as high as 40 mg/kg (45) . N 2 O-induced antinociception and antagonism of that antinociceptive effect have been most prominently demonstrated in rats using the hot plate paradigm, tail withdrawal from warm water, and the radiant heat tail flick test. In these models, antinociception is indicated by a significant prolongation in the latency time to reaction (hindpaw lick or escape attempt, tail withdrawal, and tail flick, respectively) to the thermal noxious stimulus. A general characteristic of N 2 O-induced antinociception in rats was the steep dose dependency of the drug effect.
QUOCK AND VAUGHN
The most consistent antinociceptive effect was in response to 70-75% N 2 O, whereas 50% N 2 O evoked a highly variable response and lower concentrations were generally ineffective (32, 48, 81) .
The antinociceptive effect of N 2 O in rats is also sensitive to antagonism by naloxone and naltrexone. As in mice, the antagonism of N 2 O in the rat tail flick test required higher systemic doses (5-10 mg/kg) than required for antagonism of morphine (4, 81) . In rats implanted with central microinjection cannulae, the antinociceptive effect of 70% N 2 O in the hot plate test was significantly antagonized by i.c.v. doses of 5.0 and 10 µg of naltrexone; increasing the i.e. v. dose of naltrexone to 20 µg failed to increase the antagonism (32) . When 20 ng naloxone was administered into the cisternum, the antinociceptive effect of N 2 O in the tail flick test was immediately terminated (48) .
Tolerance and cross-tolerance studies conducted in the mouse abdominal constriction and rat tail flick paradigms suggest that N 2 O might act indirectly on opioid receptors via stimulated release of opioid peptides. Chronic injections of up to 400 mg/kg morphine daily or s.c. implantation of 75-mg morphine pellets rendered animals tolerant to morphine-induced antinociception and also cross-tolerant to N 2 O-induced antinociception. However, after exposure to 75% N 2 O for 16-18 h, animals became tolerant to the antinociceptive effect of 80% N 2 O but they were not cross-tolerant to morphineinduced antinociception (3, 4) . Therefore, N 2 O tolerance induced by chronic exposure to N 2 O resulted mainly from depletion of the releasable pool of endogenous opioid peptides with no concomitant change in responsiveness of opioid receptors to morphine. Consequently, in N 2 O-tolerant animals, morphine continued to produce antinociception. On the other hand, morphine tolerance reduced responsiveness to the antinociceptive effects of both morphine and opioid peptides released by N 2 O. N 2 O-induced release of opioid peptides has been demonstrated in both in vivo and in vitro preparations. Exposure to 75% N 2 O increased the amount of immunoreactive (IR) methionine-enkephalin (ME) in fractions of artificial cerebrospinal fluid (CSF) collected from urethane-anesthetized, ventricular-cisternal perfused rats (59) . Based on kinetic modeling, the rate of neuronal release of ME in this in vivo system was increased by 140% in the presence of 75% N 2 O (71). Comparable findings were reported in chronically cannulated dogs exposed to 66-75% N 2 O (15), where there were significantly elevated levels of IR ME and [Arg ]ME in CSF samples collected from the third ventricle. In in vitro studies, exposure to increasing concentrations of N 2 O was shown to increase quantities of IR /3-endorphin (/3-EP) released from superfused rat basal hypothalamic cells (82) .
Results from pharmacological studies also support the hypothesis of an indirect action of N 2 O on opioid recep-tors. N 2 O-induced antinociception in rats was attenuated in a dose-related manner by i.e. v. pretreatment with 50-200 µ,g of rabbit antiserum selective for {3-EP. In addition, i.e. v. pretreatment with the endopeptidase 24.11-inhibitor phosphoramidon significantly potentiated N 2 O-induced antinociception in rats (21) . Paradoxically, N 2 O-induced antinociception was not blocked by a ME antibody in i.c.v . doses as high as 400 µ,g (26) .
An alternative explanation is that N 2 O acts directly on the opioid receptor (22 (1) and resulted in appearance of an additional superhigh-affinity binding site for. [ 3 H]naloxone in rat forebrain (10) . In a more recent study of brain µ, -opioid and K -opioid receptors, 100% N 2 O or 2% halothane in oxygen was bubbled through tissue homogenate prepared from whole guinea pig brain (49 
The Role of Multiple Opioid Receptor Subtypes in N 2 0-Induced Antinociception
The observation that N 2 O-induced antinociception was sensitive to antagonism by opioid receptor blockers was the initial indicator and strongest evidence for mediation by endogenous opioid mechanisms. However, the s.c. doses of both naloxone and naltrexone required for antagonism of N 2 O-induced antinociception were greater than those needed to antagonize morphine. Also, the antagonism was always partial, never complete. There are two possible explanations for this incomplete antagonism of N 2 O antinociception by opioid receptor blockers. One, N 2 O-induced antinociception might be only partly determined by opioid mechanisms and may involve a nonopioid component. Two, N 2 O-induced antinociception might be mediated by opioid receptors other than the classical µ,-opioid receptor. It is now acknowledged that naloxone and naltrexone can block µ, -opioid receptors at low doses, but the dose of each must be increased in order to occupy non-µ,-opioid receptor types (53) . The introduction of newer, subtype-selective antagonists has made it possible to more precisely identify the central opioid receptors that mediate N 2 Oinduced antinociception.
One difficulty in determining the opioid receptors that mediate N 2 O-induced antinociception is that identifica-153 tion of opioid receptor subtypes depend on the type and intensity of noxious stimulus applied. It was previously suggested that different opioid receptor subtypes participate in supraspinal and spinal antinociceptive responses depending upon whether the test utilized chemical or thermal stimuli to evoke pain (78) . For instance, antinociception in the rat abdominal constriction test (chemical stimulus) is mediated byµ,-and K-opioid, but not oopioid, receptors (65) , whereas spinal antinociception in the hot plate test (thermal stimulus) is mediated byµ, and o, but not K, receptors (65) . More current research has demonstrated that K -opioid receptor-mediated antinociception is intensity dependent in thermal nociceptive tests (43, 52) . On the other hand, studies to date show that even "selective" o-opioid agonists possess a residual cross-reactivity at µ,-opioid receptors (11), possibly providing an explanation to those reports of an antinociceptive effect of o-opioid agonists in tests utilizing chemical noxious stimuli (54) . Interpretation is further complicated by findings of modulatory interactions between different opioid receptor subtypes (31, 33) . . These results support the concept of a descending opioid system that can inhibit antinociception (17) (18) (19) . Spinal opioid receptors in this system are ultrasensitive to antagonism by naloxone at doses so extremely low that antinociception induced by administration of classical µ,-and K-opioid agonists is not antagonized. Hence, ultralow doses of naloxone inactivate this antinociception-inhibitory system and potentiate the antinociceptive effects of both N 2 O and U-50,488H.
N 2 O-Induced Antinociception in Rats
Subtype-selective opioid antagonists have also been used to study N 2 O-induced antinociception in the rat hot plate paradigm. CTOP is a somatostatin analogue that can preferentially block µ, -opioid receptors (37) and selectively antagonize the effects of morphine and the µ,-selective opioid agonist DAMGO ([o-Ala 2 MePhe4,Glyol5]enkephalin) in rats (14) . Administration i.e. v. of 1 µ,g CTOP significantly attenuated the antinociceptive effect of 700Jo N 2 O; increasing the dose to 5 µ,g CTOP failed QUOCK AND VAUGHN to increase the degree of antagonism. When CTOP was microinjected directly into the periaqueductal gray (PAG), a known site of action of morphine antinociception (30, 80) , N 2 O-induced antinociception was antagonized in dose-dependent manner up to an intracerebral dose of 1.0 µ,g (32) . This localization of µ, -opioid receptors involved in N 2 O-induced antinociception to the P AG is consistent with findings that kainic acid lesions of the P AG significantly reduce N 2 O-induced antinociception in the tail flick test (81) . N 2 O-induced antinociception may also be mediated by the 1:-opioid receptor. ,6-Endorphin(l-27) [,6-EP(l -27)] is a molecule of ,6-EP that is truncated by four amino acids at the C-terminal. This peptide selectively antagonizes the effects of ,6-EP and is a putative 1:-opioid receptor blocker (70) . At i.c.v. doses below 5.0 µ,g, ,6-EP(l-27) produced dose-related antagonism of N 2 O-induced antinociception in the rat hot plate test. At i.e. v. doses greater than 5.0 µ,g, the antagonistic activity of ,6-EP(l-27) was gradually reduced and ,6-EP(l-27) produced a dose-related increase in the antinociceptive response to 700Jo N 2 O. Rats pretreated with 7.0 µ,g ,6-EP(l -27) i.c.v. demonstrated the greatest variability of responsiveness to 700Jo N 2 O, suggesting that 7.0 µ,g is near the threshold dose separating antagonistic and potentiatory influences upon N 2 O-induced antinociception (32) . These data are consistent with earlier findings that ,6-EP(l-27) has partial agonist activity and can cause antinociception at higher doses (25, 70) . Although ,6-EP(l-27) administered i.e. v. reduced N 2 O-induced antinociception, comparable doses administered directly into the P AG had no effect on N 2 O-induced antinociception. ,6-EP(l-27) was not effective in reducing N 2 O antinociception when administered directly into the PAG. Though the 1:-opioid receptors involved in N 2 O-induced antinociception do not seem to reside in the P AG, possible sites might include the raphe obscurus nucleus and raphe pallidus nucleus in the caudal medulla oblongata or the medial posterior nucleus accumbens, medial preoptic area, and arcuate hypothalamic nucleus in the forebrain , which are active sites where administration of ,6-EP inhibits the tail flick response in rats (76, 77) .
In contrast to the µ,-opioid and 1:-opioid receptors that appear to mediate N 2 O antinociception in the hot plate test, other opioid receptor subtypes seem to be involved in other tests . Subsequent pharmacogenetic studies on N 2 O-induced antinociception have focused on C57BL/6J and DBA/ 2J strains. These strains are particularly useful for the study of the genetic determinants of N 2 O responsiveness for several reasons. First, they have large differences in responsiveness to N 2 O with the C57BL/ 6J strain being much more sensitive to N 2 O-induced antinociception than the DBA/2J strain. Second, these strains have been compared extensively for differences in morphineinduced antinociception (the DBA/2J is more sensitive), morphine-induced locomotor activation (the C57BL/ 6J is more sensitive), and susceptibility to development of morphine tolerance and physical dependence (8, 24) . Third, crosses of the C57BL/6J and DBA/2J strains have resulted in 26 B x D recombinant inbred (RI) stains. Each RI strain is a random recombination of the progenitor chromosomes in a homozygous state as a result of redistribution of the original F 2 genetic variance so that it exists almost entirely between strains and is almost completely absent within strains. Finally, a large number of marker gene loci have now been mapped (> 1200).
Preliminary studies conducted in 22 Bx D RI strains revealed a hierarchy of responsiveness to 70% N 2 O ranging from a < 10% antinociceptive response in the B x D-27 / Ty to a 100% response in the Bx D-14 and -25 / Ty lines. Cluster analysis showed one cluster of 16 strains approximating the C57BL/ 6 progenitor (61.9-100% antinociceptive response to 70% N 2 O) and another of six strains approximating the DBA/2 progenitor (9.1-40% antinociceptive response to 70% N 2 O) (62) . The robust strain differences permitted screening the strain antinociceptive means with marker gene loci previously mapped in Bx D RI strains . Significant associations at the 0.002 level were found on seven chromosomes, suggesting the presence of quantitative trait loci (QTL). As the number of test subjects in each RI strain is 155 increased, the number of promising QTL will be further restricted and confirmed .
The Role of NO in N 2 0-lnduced Antinociception
A related but far more reactive oxide of nitrogen is NO, which consists of a single nitrogen atom coupled to a single oxygen atom. In recent years, NO has been recognized as being an important biological regulator in macrophage cytotoxic activity, physiological and pharmacological vasodilation, and inhibition of platelet aggregation (34, 44) . Current neurobiological research has also identified NO as an intracellular messenger and even a new type of neurotransmitter in both the peripheral and central nervous systems (7 ,20) . Central to investigations of NO function are drugs that inhibit the key enzyme NO synthase (NOS); these include the substituted arginines L-N°-nitro arginine (L-NOARG), L-N°-nitro arginine methyl ester (L-NAME), L-N°-monomethyl nitro arginine (L-NMMA), and 7-nitro indazole.
There is recent evidence of a modulatory role played by NO in N 2 O-induced antinociception. In the mouse abdominal constriction paradigm, s.c. pretreatment Pretreatment with 10 mg/kg L-NOARG, s.c., failed to influence the antinociceptive effects of two other opioid drugs, the predominantly µ-opioid agonist morphine and the K-selective opioid agonist U-50,488H (41) . The failure of NOS inhibition to reduce the antinociceptive effects of these direct-acting opioid receptor agonists mitigates against the idea that NO is a general mediator in central pathways that mediate opioid antinociception. What then is the role of NO in N 2 O-induced antinociception? One possible explanation is that NO might play a role in the mechanism of neuronal release of opioid peptides . Tseng and his associates have shown that {3-EP-induced antinociception is related to stimulated release of ME in the spinal cord and activation of spinal o-opioid receptors by ME (74, 75) . In urethane-anesthetized, i.t.-perfused rats, i.c.v. {3-EP-induced increase of ME levels in the i.t. perfusate was significantly suppressed by perfusing with artificial CSF containing 100 µM L-NOARG (27 ,28,39) . The addition of 50 mM L-arginine, but not o -arginine, into the CSF perfusate reversed the suppression of the ME increase by L-NOARG. On the other hand, increasing the perfusate concentration of L-NOARG to 250 µM failed to produce a greater suppression of the {3-EP-induced increase in ME. These findings suggest that NO may mediate the {3-EP-induced release of ME in the spinal cord. If {3-EP is the key opioid mediator in N 2 O in rats, as suggested by in vitro release (82) and antibody antagonism studies (26) , such a role for NO might explain the antagonism of N 2 O antinociception in rats by NOS inhibitors .
Other research has uncovered an apparent role for NO in hyperalgesia at the level of the spinal cord. Synaptic plasticity may be intimately involved in the mechanism of chronic pain; in a manner analogous to the role it plays in long-term potentiation, NO may act as a retrograde messenger to maintain a high level of presynaptic activity in hyperalgesia (42) . A proactive role of NO in hyperalgesia is supported by observations of an antinociceptive effect of NOS inhibitors in mouse tail flick, hot plate, abdominal constriction, and formalin-induced paw lick tests (46, 47) . However, the standard challenge doses of L-NAME were generally 50-100 mg/kg, which was 5-10 times greater than the IO mg/kg dose used in our studies, and the resulting antinociceptive effects were not sensitive to antagonism by naloxone.
Summary
Twenty years ago, N 2 O was merely one of a number of inhalation anesthetics that was distinguished by an unfavorable minimum alveolar concentration and the necessity of combining it with a more potent anesthetic QUOCK AND VAUGHN agent to produce surgical anesthesia. Recent research, however, has revealed additional central pharmacological actions (analgesia, anxiolysis) that broaden the clinical applications of N 2 O. There is increasing evidence of an opioid basis to the analgesic effect of N 2 O. Yet N 2 O appears to be strikingly unlike any other pharmacological agent with opioid analgesic properties. It has become increasing apparent that N 2 O is not only a clinically useful anesthetic and analgesic agent but also a unique investigative tool for studying opioid mechanisms. Elucidation of its uncommon mechanism of interaction with opioid systems will produce a better understanding of the opioid systems themselves .
